^
Association details:
| Biomarker: | GPR176 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Assessment of delayed bleeding after endoscopic submucosal dissection of early-stage gastrointestinal tumors in patients receiving direct oral anticoagulants
Published date:
06/08/2023
Excerpt:
In summary, the high GPR176 expression level was associated with poor prognosis, more robust immune infiltration, and worse immunotherapy efficacy in GC patients, suggesting that GPR176 may be an immune-related biomarker for GC that can promote the proliferation, migration, and invasion of GC cells.
DOI:
10.1038/s41598-023-36586-3
Source:
Title:
Exploring the Correlation Between GPR176, a Potential Target Gene of Gastric Cancer, and Immune Cell Infiltration
Published date:
06/01/2023
Excerpt:
Additionally, individuals with high expression of GPR176 had a worse 10-year overall survival (OS), in contrast with those having a low expression of GPR176 (p < 0.001). The OS of GC can be predicted using a validated nomogram model. The expression of GPR176 demonstrated a negative correlation with CD8+ T cells...By examining GPR176 from various biological perspectives, it was determined that GPR176 can act as a predictive biomarker for poor patient prognosis in GC.
DOI:
10.2147/PGPM.S411199
